Cannabinoid-based formulation
OwnerCharles MORGAN, Melissa STURGESS +1inventors
InventorsCharles MORGAN, Melissa STURGESS, Nicholas CLARKSON
Life of this patent
Estimating the term…
Abstract
The invention relates to cannabinoid-based formulations, and particularly, although not exclusively, to methods for preparing cannabinoid-based formulations, and to the formulations per se, and their use in therapy. The invention is especially concerned with cannabidiol (CBD)-based formulations, their manufacture and uses, for treating pain, inflammation, autoimmune diseases, neurological diseases, neoplasm, nausea, hypertension, hypertrophic cardiomyopathy, or fibrosis.
Claims29
A cannabinoid-based formulation comprising:
- (i) one or more cannabinoid;
- and
- (ii) a plurality of terpenes selected from a group of terpenes consisting of:
- myrcene;
- caryophyllene;
- ocimene;
- pinene;
- limonene;
- humulene;
- and linalool;
- wherein the formulation substantially lacks THC.
The cannabinoid-based formulation according to any preceding claim, wherein the formulation comprises no detectable THC using reasonable means of analysis.
The cannabinoid-based formulation according to any preceding claim, wherein the one or more cannabinoid is selected from a group of cannabinoids consisting of:
- cannabidiol (CBD);
- cannabichromene (CBC);
- cannabigerol (CBG);
- and cannabigerol monomethyl ether (CBGM).
The cannabinoid-based formulation according to any preceding claim, wherein the one or more cannabinoid comprises CBD.
The cannabinoid-based formulation according to any preceding claim, wherein the one or more cannabinoid comprises an isolate of cannabidiol (CBD).
The cannabinoid-based formulation according to any preceding claim, wherein the formulation does not comprise CBC, CBG, or CBGM.
The cannabinoid-based formulation according to any preceding claim, wherein the purity of the one or more cannabinoid is at least 97%, at least 98% or at least 99%, or about 98-100%.
The cannabinoid-based formulation according to any preceding claim, wherein the concentration of the one or more cannabinoid, preferably CBD, in the cannabinoid-based formulation is at least 2% (w/v), at least 3% (w/v) or at least 4% (w/v).
The cannabinoid-based formulation according to any preceding claim, wherein the concentration of the one or more cannabinoid, preferably CBD, in the cannabinoid-based formulation is at least 5% (w/v), at least 6% (w/v) or at least 7% (w/v).
The cannabinoid-based formulation according to any preceding claim, wherein the concentration of the one or more cannabinoid, preferably CBD, in the cannabinoid-based formulation is at least 8% (w/v), at least 9% (w/v) or at least 10% (w/v).
The cannabinoid-based formulation according to any preceding claim, wherein the concentration of the one or more cannabinoid, preferably CBD, in the cannabinoid-based formulation is between 7 and 13% (w/v), or between 8 and 12% (w/v).
The cannabinoid-based formulation according to any preceding claim, wherein the concentration of the one or more cannabinoid, preferably CBD, in the cannabinoid-based formulation is between 9 and 11% (w/v).
The cannabinoid-based formulation according to any preceding claim, wherein the purity of the plurality of terpenes may be at least 90%, at least 92% or at least 95% of total terpenes.
The cannabinoid-based formulation according to any preceding claim, wherein the plurality of terpenes comprises at least three, at least four, or at least five terpenes selected from a group of terpenes consisting of:
- myrcene;
- caryophyllene;
- ocimene;
- pinene;
- limonene;
- humulene;
- and linalool.
The cannabinoid-based formulation according to any preceding claim, wherein the plurality of terpenes comprises at least six, or at least seven terpenes selected from a group of terpenes consisting of:
- myrcene;
- caryophyllene;
- ocimene;
- pinene;
- limonene;
- humulene;
- and linalool.
The cannabinoid-based formulation according to any preceding claim, wherein:
- (i) the pinene is α-Pinene, optionally wherein the concentration of α-Pinene in the cannabinoid-based formulation is at least 0.0001 (w/v), at least 0.001% (w/v), at least 0.01% (w/v), less than 0.75% (w/v), less than 0.5% (w/v), less than 0.3% (w/v), between 0.0001 and 0.5% (w/v), between 0.01 and 0.3% (w/v), between 0.01 and 0.2% (w/v), between 0.01 and 0.05% (w/v), between 0.01 and 0.04% (w/v), or between 0.01 and 0.03% (w/v);
- (ii) the concentration of limonene in the cannabinoid-based formulation is at least 0.0001 (w/v), at least 0.001% (w/v), at least 0.01% (w/v), less than 0.75% (w/v), less than 0.5% (w/v), less than 0.3% (w/v), between 0.0001 and 0.5% (w/v), between 0.01 and 0.3% (w/v), between 0.01 and 0.2% (w/v), between 0.01 and 0.05% (w/v), between 0.01 and 0.04% (w/v), between 0.01 and 0.03% (w/v), between 0.03 and 0.09% (w/v), between 0.03 and 0.08% (w/v), or between 0.03 and 0.07% (w/v);
- (iii) the ocimene is β-Ocimene, optionally wherein the concentration of β-Ocimene in the cannabinoid-based formulation is at least 0.0001 (w/v), at least 0.001% (w/v), at least 0.01% (w/v), less than 0.75% (w/v), less than 0.5% (w/v), less than 0.3% (w/v), between 0.0001 and 0.5% (w/v), between 0.01 and 0.3% (w/v), between 0.01 and 0.2% (w/v), between 0.01 and 0.07% (w/v), between 0.01 and 0.06% (w/v), between 0.01 and 0.05% (w/v), between 0.01 and 0.04% (w/v), between 0.001 and 0.05% (w/v), between 0.001 and 0.04% (w/v), between 0.001 and 0.02% (w/v), or between 0.001 and 0.01% (w/v);
- (iv) the caryophyllene is β-Caryophyllene, optionally wherein the concentration of β-Caryophyllene in the cannabinoid-based formulation is at least 0.0001 (w/v), at least 0.001% (w/v), at least 0.01% (w/v), less than 0.75% (w/v), less than 0.5% (w/v), less than 0.3% (w/v), between 0.0001 and 0.5% (w/v), between 0.01 and 0.3% (w/v), between 0.01 and 0.2% (w/v), between 0.01 and 0.08% (w/v), between 0.01 and 0.07% (w/v), between 0.01 and 0.06% (w/v), between 0.01 and 0.05% (w/v), between 0.01 and 0.1% (w/v), between 0.01 and 0.09% (w/v), between 0.01 and 0.08% (w/v), or between 0.03 and 0.08% (w/v);
- (v) the humulene is Alpha-Humulene, optionally wherein the concentration of Alpha-Humulene in the cannabinoid-based formulation is at least 0.0001 (w/v), at least 0.001% (w/v), at least 0.01% (w/v), less than 0.75% (w/v), less than 0.5% (w/v), less than 0.3% (w/v), between 0.0001 and 0.5% (w/v), between 0.01 and 0.3% (w/v), between 0.01 and 0.2% (w/v), between 0.01 and 0.04% (w/v), between 0.01 and 0.03% (w/v), between 0.01 and 0.02% (w/v), between 0.005 and 0.04% (w/v), between 0.005 and 0.03% (w/v) or between 0.005 and 0.02% (w/v);
- (vi) the myrcene is β-Myrcene, optionally wherein the concentration of β-Myrcene in the cannabinoid-based formulation is at least 0.0001 (w/v), at least 0.001% (w/v), at least 0.01% (w/v), less than 0.75% (w/v), less than 0.5% (w/v), less than 0.3% (w/v), between 0.0001 and 0.5% (w/v), between 0.01 and 0.3% (w/v), between 0.01 and 0.2% (w/v), between 0.01 and 0.1% (w/v), between 0.01 and 0.08% (w/v), between 0.01 and 0.07% (w/v), or between 0.01 and 0.06% (w/v);
- and/or
- (vii) the concentration of linalool in the cannabinoid-based formulation is at least 0.0001 (w/v), at least 0.001% (w/v), at least 0.01% (w/v), less than 0.75% (w/v), less than 0.5% (w/v), less than 0.3% (w/v), between 0.0001 and 0.5% (w/v), between 0.01 and 0.3% (w/v), between 0.01 and 0.2% (w/v), between 0.01 and 0.05% (w/v), between 0.01 and 0.04% (w/v), between 0.01 and 0.03% (w/v), or between 0.01 and 0.02% (w/v).
The cannabinoid-based formulation according to any preceding claim, wherein the cannabinoid-based formulation further comprises a pharmaceutically acceptable excipient or carrier.
The cannabinoid-based formulation according to any preceding claim, wherein the cannabinoid-based formulation is in a liquid form, and optionally comprises a tincture.
The cannabinoid-based formulation according to any preceding claim, wherein the formulation is administrable by sublabial, buccal, sublingual, or oropharyngeal administration delivery.
Dependencies are inferred from the claim text.